Immuno-oncology
Conference Coverage
Adding ipilimumab to nivolumab provides no benefit in SCC trial
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
Conference Coverage
Pembro as good as chemo for gastric cancers with less toxicity
CHICAGO – Pembrolizumab is now at least an alternative to chemotherapy, if not preferred, in many of these patients...
News
Do some EGFR mutation subtypes benefit from immune checkpoint blockade?
One common EGFR tyrosine kinase inhibitor–sensitizing allele may be associated with similar benefit versus EGFR wild-type lung tumors, analysis...
Conference Coverage
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
ATLANTA – Preclinical data suggest a role for SRA737 plus anti–PD-L1 therapy and low-dose gemcitabine in SCLC.
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
Conference Coverage
Pooled KEYNOTE data support pembro for elderly patients with NSCLC
GENEVA – Investigators analyzed data from 264 patients 75 years or older involved in the KEYNOTE-010, KEYNOTE-024,...
News
FDA approves pembrolizumab for first-line stage III NSCLC
Approval was based on improved overall survival for patients taking pembrolizumab, compared with those taking the investigators’ choice of...